Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Creative Biolabs is accelerating CAR‑T innovation, driving breakthroughs in solid tumor targeting. SHIRLEY, NY, UNITED ...

The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...

Symptoms and organ damage abated in young children and teenagers whose conditions had resisted other treatments.

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

Patients relapsing within three months post-CAR T-cell therapy have lower response rates to BsAb therapy compared to those relapsing after six months. Elevated LDH levels and higher international ...

According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%.